Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
U.S. funds work on two Zika vaccines
by Ann M. Thayer
September 12, 2016
| A version of this story appeared in
Volume 94, Issue 36
The Biomedical Advanced Research & Development Authority has committed to supporting two companies’ early-stage development of Zika vaccines. Japan’s Takeda Pharmaceutical will receive $20 million over 18 months to complete preclinical work and a Phase I clinical trial of its inactivated whole-virus vaccine. BARDA is also putting $8 million over four years into similar work at Moderna Therapeutics on its mRNA-based vaccine. BARDA may extend the agreements for another five to six years, putting Takeda in a position to receive up to $311 million and Moderna up to $126 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter